How National Health Insurance Coverage Policy Affected the Use of Trastuzumab and Rituximab in China: A Bicentric Retrospective Study

BACKGROUND: Cancer is a significant health concern and is China’s leading cause of mortality. Targeted therapies, such as trastuzumab and rituximab, have enhanced clinical treatment efficacy. However, their high costs burden patients and healthcare systems considerably. Patient demographic factors f...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Linlin, Lin, Yingtao, Fang, Wenqing, Liu, Yanyan, Bao, Yuwen, Li, Xin, Zhang, Yuanyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488736/
https://www.ncbi.nlm.nih.gov/pubmed/37692767
http://dx.doi.org/10.2147/RMHP.S420899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488736/
https://www.ncbi.nlm.nih.gov/pubmed/37692767
http://dx.doi.org/10.2147/RMHP.S420899

Ejemplares similares